Background-About half of people with Down syndrome (DS) exhibit some form of congenital heart disease (CHD); however, trisomy for human chromosome 21 (Hsa21) alone is insufficient to cause CHD, as half of all people with DS have a normal heart, suggesting that genetic modifiers interact with dosage-sensitive gene(s) on Hsa21 to result in CHD. We hypothesize that a threshold exists in both DS and euploid populations for the number of genetic perturbations that can be tolerated before CHD results. Methods and Results-We ascertained a group of individuals with DS and complete atrioventricular septal defect and sequenced 2 candidate genes for CHD: CRELD1, which is associated with atrioventricular septal defect in people with or without DS, and HEY2, whose mouse ortholog (Hey2) produces septal defects when mutated. Several deleterious variants were identified, but the frequency of these potential modifiers was low. We crossed mice with mutant forms of these potential modifiers to the Ts65Dn mouse model of DS. Crossing loss-of-function alleles of either Creld1 or Hey2 onto the trisomic background caused a significant increase in the frequency of CHD, demonstrating an interaction between the modifiers and trisomic genes. We showed further that, although each of these mutant modifiers is benign by itself, they interact to affect heart development when inherited together. Conclusions-Using mouse models of Down syndrome and of genes associated with congenital heart disease, we demonstrate a biological basis for an interaction that supports a threshold hypothesis for additive effects of genetic modifiers in the sensitized trisomic population. (Circ Cardiovasc Genet. 2012;5:301-308.)
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Attempts to identify dosage-sensitive Hsa21 genes that contribute to CHD have generally focused on individuals with partial trisomy for Hsa21 to identify critical regions: the smallest regions of overlap between individuals who share a DS-associated phenotype [3] [4] [5] ; however, the resolution of this approach is limited by the rarity of the condition, the complex karyotype of such individuals (usually including other chromosomal anomalies in addition to partial trisomy 21) , and the heterogeneity of the phenotype. Several heart-critical regions have been defined, including a minimal region of just 1.7 Mb from DSCAM to PKNOX1 that is based on individuals with DS and a variety of CHDs. 3 To date, this kind of analysis has not considered additional (disomic) genetic modifiers that have been associated with CHD.
One such genetic modifier is cysteine-rich with EGF-like domains 1 (CRELD1), initially identified as a candidate for the AVSD2 locus. 6 Missense mutations in CRELD1 cause protein misfolding 6 and are associated with AVSD in some individuals but are also present in unaffected family members. 7, 8 This finding suggests that CRELD1 is neither necessary nor sufficient to cause AVSD but may increase the risk of developing a defect, making it a reasonable candidate as a susceptibility locus (modifier) for AVSD. Indeed, in an earlier study, we detected mutations in CRELD1 in a small population of people with DS and CHD. 2 Other genetic modifiers have been shown to affect heart development in either individuals with DS or model organisms. For example, somatic mutations in HEY2 have been identified in CHD in people with DS but not in euploid populations with heart defects, 9, 10 and Hey2 Ϫ/Ϫ mice die in early postnatal stages from cardiac abnormalities that always include septal defects. 11, 12 Animal models are crucial to our understanding of the pathogenesis of CHD and the molecular mechanisms underlying these conditions. Orthologs of many genes on Hsa21 are found on mouse chromosome 16 (Mmu16), with smaller subsets on Mmu10 and Mmu17. 13 The most widely used DS mouse model, Ts65Dn, is trisomic for a segment of Mmu16 containing about half of the Hsa21 orthologs. 14 Ts65Dn mice display a number of the features of DS, including cardiac abnormalities, albeit at a lower frequency than in humans. 15 The information derived from mouse models suggests that, in mouse as in human, heart phenotypes likely result from a complex genetic insult, of which dosage imbalance represents only a part. Additional genetic and environmental factors must contribute to these phenotypes. In DS, polymorphic disomic loci on other chromosomes may act as genetic modifiers when combined with trisomic genes.
We have created a null allele of mouse Creld1 to study the contributions of this gene to developmental processes (Redig and Maslen, submitted). Homozygous Creld1 Ϫ/Ϫ embryos die by embryonic day 11.5 and exhibit several defects, including perturbations in heart development. In particular, the endocardial cushions form but are hypocellular, with few mesenchymal cells evident. Little more is known about Creld1 function during development and how it affects heart formation. Further, there is no description of whether and how Creld1 interacts with Hsa21 genes in normal heart development.
We hypothesize that a threshold exists, in both DS and euploid populations, for the number of genetic perturbations that can be tolerated before CHD results ( Figure 1 ). In this model, CHD in euploid individuals is caused by multiple additive factors that could be genetic, environmental, or entirely stochastic. Given the significant increased risk for CHD in people with trisomy 21, the DS population can be said to be sensitized, creating a greater signal-to-noise ratio for smaller risk factors. Identification of modifiers should therefore be enhanced in DS using genome-wide association studies, candidate gene sequencing in affected and control populations, and modeling of candidate gene mutations in the mouse. Here, we provide evidence supporting this additive hypothesis and demonstrate the use of this approach to confirm results from both human resequencing and mouse mutation analysis.
Materials and Methods

Patient Recruiting
Human subjects were recruited nationally through the Down Syndrome Heart Project (DSHP) (http://inertia.bs.jhmi.edu/ds/ index.html). Individuals with DS due to an extra intact copy of Hsa21 verified by karyotype were included as cases if they had complete atrioventricular canal (DSϩAVSD) and as controls if they had DS and a normal echocardiogram. All surgical records or echocardiograms were reviewed and confirmed by a pediatric cardiologist. All cases and controls were non-Hispanic whites. Consents and procedures were approved by Institutional Review Boards at the Johns Hopkins University School of Medicine, Emory University, and Oregon Health & Science University.
Resequencing Summary
Human CRELD1 and HEY2 genes were resequenced, including all coding regions and at least 50 bp into each flanking intron and untranslated regions (UTR) to cover interstitial regulatory elements ( Figure 2 and online-only Data Supplement Table I ). Analyses were done by standard DNA sequencing of polymerase chain reaction (PCR)-amplified genomic DNA by the Oregon Clinical Translational Research Institute sequencing core facility. Electropherograms were transferred electronically for detailed analysis facilitated by the MutationSurvey or software suite (Soft Genetics). All sequences were compared with a reference sequence, and all variants were noted and further analyzed. Variants of interest were confirmed by resequencing a newly prepared amplicon. With 1 exception, all variants reported were heterozygous ( Table 1) .
Variants were categorized by the type of variant, and documented single-nucleotide polymorphism (SNPs) were annotated by query of the SNP database. We compared SNP frequency to identify any allelespecific disease associations. Variants were categorized as missense, insertion/deletion, noncoding, splice site, regulatory, and other and prioritized for disease-association potential (ie, the likelihood that the variant will alter gene expression or protein product structure or function). Missense variants were analyzed using the Polyphen (http:// genetics.bwh.harvard.edu/pph/) and SIFT (http://sift.jcvi.org/) algo- Figure 1 . A threshold model for CHD. We hypothesize that the human population includes allelic variants in multiple genes that contribute to the risk of congenital heart disease, many of which have subtle or no effects by themselves. Additive effects of individual modifier genes can reach a threshold whereby heart septal development is disrupted (Euploidy with congenital heart disease [CHD]), but the likelihood of inheriting many predisposing modifiers is small. Trisomy 21 is a significant risk factor for CHD, but alone is not sufficient to produce heart defects; however, those people with an extra copy of Hsa21 may require fewer disomic or trisomic modifiers to reach the threshold (Ts21ϩmodifier). The relative contribution of the modifier in the sensitized Down syndrome population is therefore more readily detectable.
rithms for predictions of likelihood of damage to the protein product. We also monitored lack of expected SNP occurrence as an indicator of gene deletion. All variants were analyzed in control individuals (DS without heart defects) using DNA resequencing of the amplicon, encompassing the alteration, allele-specific PCR analysis or restriction enzyme digestion, as previously described. 7
Animal Husbandry
Mice were maintained in an AAALAS-certified clean facility with food and water ad libitum. Ts65Dn mice (B6EiC3H-a/A-Ts65Dn, Jackson Laboratory) were maintained on the B6;C3H background. Mice used in this study were the progeny of female Ts65Dn mice. Creld1 null mice were generated by gene targeting (J. Redig, PhD, and C.L. Maslen, PhD, unpublished data; see online-only Data Supplement Figure I ) and backcrossed a minimum of 8 generations onto a C57BL/6J background. Mice bearing a null allele of Hey2 were generated by gene targeting. 16 All procedures were approved by the Institutional Animal Care and Use Committee.
Genotyping
Genomic DNA was extracted from tail tips of mice and was used for genotyping by PCR. Ts65Dn mice were identified by both PCR and fluorescence in situ hybridization as described. 17, 18 Genotypes of Creld1 and Hey2 knockout mice were determined by PCR. For Creld1 genotyping, 2 sets of primers that amplify the deleted region of Creld1 and a portion of the neomycin resistance gene were added together in each reaction. Resequencing strategy for CRELD1 and HEY2. We assessed coding regions of these genes, including all exons with 50ϩ bp of sequence in the flanking introns, the 5Ј untranslated region (UTR) and 50ϩ bp of the 3Ј UTR. A, Resequencing strategy for CRELD1; B, Resequencing strategy for HEY2. For exact coordinates, see online-only Data Supplement Table I 
Histology
The progeny of various crosses were collected at postnatal day (P) 0 within hours of birth. Pups were euthanized, and thoraxes were removed and fixed in 10% formalin. Tissues were embedded in paraffin and sectioned at 7 m by standard methods, followed by staining with hematoxylin and eosin using standard methods. Heart morphology for each animal was analyzed under a dissecting stereomicroscope by at least 2 individuals blinded to genotypes to evaluate the frequency and severity of phenotypes. Photos were taken using a Nikon Digital Sight system.
Real-Time Analysis of Gene Expression
Total RNA was extracted from the L-cells or the hearts of 4-weekold mice with different genotypes by using TRIzol reagent (Invitrogen). cDNA synthesis was carried out with the First-Strand cDNA synthesis kit (Life Sciences) using 8 g of total RNA as template. PCR was carried out using TaqMan Gene Expression Assays (Applied Biosystems) on a 7500 Real-Time PCR System (Applied Biosystems). For the Creld1 and Hey2 coregulation study, fluorescent (FAM)-labeled Creld1, Hey2, Notch1, and GAPDH were normalized to a VIC-labeled internal control, ␤-actin. GAPDH was used as a negative control. All comparisons refer to the wild type (WT).
Cell Culture and Western Blotting
L-cells were a gift of Dr Gerry Weinmaster and were grown in Dulbecco's Modified Eagle Medium with high glucose and 10% heat-inactivated fetal bovine serum (FBS), supplemental nonessential amino acids and penicillin/streptomycin (Invitrogen) at 37°C and 5% CO 2 . The pCS2 ϩ /Hey2 construct was kindly provided by Dr Manfred Gessler. The pCS2 ϩ or pCS2 ϩ /Hey2 construct was transfected into the L-cells by Lipofectamine Ltx (Invitrogen). Fortyeight hours later, half of the transfected cells were harvested and total RNA was extracted; the other half was lysed in RIPA buffer (Invitrogen) for Western Blot. The anti-Hey2 antibody was purchased from PROTEINTECH (Cat. No. 10597-1-AP) and the antiactin antibody from DSHB (JLA20).
Statistical Analysis
Mendelian inheritance of alleles and trisomies were assessed by 2 tests. The prevalence of heart defects for different mouse genotypes was compared by Fisher exact test using GraphPad Prism version 5 (GraphPad Software). The relative quantification of gene expression from different genotypes was compared by Mann-Whitney test. All tests were 2-tailed, and PϽ0.05 were considered significant.
Results
Candidate Gene Mutations in a Sensitized Population
We identified genes that could be involved in congenital heart disease based on data from either human populations or mouse experimental data and chose 2, CRELD1 and HEY2, for resequencing in cases (individuals with DS and complete AVSD). The heart condition was defined by strict criteria, including 2 independent assessments of surgical notes for AVSD or a normal echocardiography report. CRELD1 was resequenced in 135 cases (DSϩAVSD), including 39 cases from a previous study 2 and 96 new cases. Four individuals each contained 1 of 3 different missense variants (online-only Data Supplement Table 1 and online-only Data Supplement Figure 2 ). One variant (p.V13M) is a known SNP (rs279552) that has been seen in equal numbers of nonsyndromic cases and controls and is predicted to be benign with regard to protein structure/function. The previously described p.R329C mutation was found in 2 cases, 1 reported before, and the other is a new occurrence in the greatly expanded population in this study. This variant was identified originally in individuals with nonsyndromic AVSD 7 and has not been identified in Ͼ400 control chromosomes. 2, 7 The p.R329C variant has been shown to affect CRELD1 protein structure. 7 In each case, the p.R329C mutation was inherited from an unaffected parent. The third missense variant, p.E414K, predicted to be damaging to the protein, was identified in 1 case among the 39 individuals examined previously and was not detected in 200 control chromosomes. As part of our candidate gene study, we also resequenced HEY2 in 90 cases (Table 1) . A single coding region variant was identified (p.L196L), which appears to be a relatively common SNP. Four noncoding variants of unknown significance were identified. All are predicted to be benign. For both HEY2 and CRELD1, all variants were heterozygous.
Reduced Expression of Creld1 Increases Septal Defects in Ts65Dn Mice
Human association studies 7, 8 and our resequencing analysis in a sensitized DS population indicate that inactivating mutations in CRELD1 may increase the likelihood of developing a septal defect in individuals with DS. We hypothesized that reduced expression of Creld1 would interact with trisomic genes in a mouse DS model to increase the occurrence of heart defects. Based on this hypothesis, we created mice carrying a null allele of Creld1 that reduces gene expression to ϳ50% of normal in heterozygotes. No expression is detected in Creld1 Ϫ/Ϫ embryos (online-only Data Supplement Figure I ). Creld1 ϩ/Ϫ mice were crossed to Ts65Dn, and progeny were collected within hours of birth, prepared for histology, and assessed for the presence of septal defects. All classes of progeny were recovered at expected frequencies (online-only Data Supplement Table III) .
A recent study detected septal defects in 1 out of 18 similarly analyzed newborn (P0) Ts65Dn mice. 15 We expanded this observation and saw a single septal defect among 25 Ts65Dn mice at P0 (combined frequency of septal defectsϭ2/43 or 4.7%) ( Table 2 ). Creld1 ϩ/Ϫ itself had no obvious effect on phenotype and none of the Creld1 ϩ/Ϫ pups that we analyzed at P0 was found to have a septal defect (nϭ45; 18 were on the B6; C3H background of Ts65Dn mice; and 27 were inbred on B6); however, the frequency of septal defects increased dramatically to 33% (6/18) in Ts65Dn, Creld1 ϩ/Ϫ mice ( Table 2) . Among those pups with heart defects, 3 had ostium secundum atrial septal defects (ASDs), and 3 had membranous ventricular septal defects (VSDs) (Table 2 and Figure 3 ). Thus, there is a significant difference in the frequency of heart defects between either Ts65Dn (Pϭ0.006) or Creld1 ϩ/Ϫ (Pϭ0.0003) mice and those with both genetic conditions (Ts65Dn, Creld1 ϩ/Ϫ ). This observation demonstrates a biological basis for a phenotypealtering interaction between the effects of trisomic genes and reduced Creld1 expression and delimits a region orthologous to part of Hsa21q22.1 (the trisomic segment in Ts65Dn) trisomy, which is sufficient to predispose to CHD.
Reduced Expression of Hey2 Increases Septal Defects in Trisomic Mice
Somatic variants of HEY2 have been identified in hearts from humans with septal defects. 9 In Hey2 Ϫ/Ϫ mice, the reported frequency (penetrance) of septal defects varies with genetic background, 11, 12, 16, 19, 20 reaching Ͼ80% on an inbred C57Bl/6J (B6) background. We detected membranous VSDs in 11 out of 14 Hey2 null neonates (79%).
We crossed a null allele of Hey2 onto the Ts65Dn trisomic background. Ts65Dn, Hey2 ϩ/Ϫ pups were underrepresented among the progeny, suggesting a deleterious additive effect of reduced Hey2 expression with the trisomic genes from Ts65Dn (online-only Data Supplement Table III ). A single null allele of Hey2 was not sufficient to cause septal defects (0 out of 45); however, the frequency of septal defects was significantly increased in Ts65Dn, Hey2 ϩ/Ϫ mice, with 6 out of 25 (24%) displaying a septal defect (Pϭ0.04 or Pϭ0.0014 compared with Ts65Dn or Hey2 ϩ/Ϫ , respectively) ( Table 2) .
Like Creld1, expression variants of Hey2 act as a modifier, contributing to CHD in a manner that is detectable on a sensitized trisomic background but not in euploid mice. Of note, membranous VSDs are the only septal defect in Hey2 Ϫ/Ϫ mice, but we detected additional structural defects in Ts65Dn, Hey2 ϩ/Ϫ . Among the 6 pups with heart defects, 3 had membranous VSDs, 1 had a muscular VSD, and 2 had ostium secundum ASDs (Table 2 and Figure 3) . Thus, the pattern, as well as the number of defects, is altered by the Hey2 trisomy interaction.
Combining Benign Creld1 and Hey2 Modifier Variants Results in Septal Defects
To test our initial hypothesis that additive effects of modifier genes contribute to CHD on a euploid background, Creld1 ϩ/Ϫ mice were crossed with Hey2 ϩ/Ϫ . Genotypes of progeny were recovered at the expected frequencies (online-only Data Supplement Table III ). No septal defects were detected at P0 in 90 pups that were either Creld1 ϩ/Ϫ (nϭ45) or Hey2 ϩ/Ϫ (nϭ45); however, 3 out of 31 double heterozygous Creld1 ϩ/Ϫ , Hey2 ϩ/Ϫ pups had a septal defect ( Table 2 ). This result indicates that Creld1 ϩ/Ϫ and Hey2 ϩ/Ϫ interact to increase the risk of CHD (Pϭ0.016, Fisher exact test, 2-tailed). Further support for an interaction comes from the observation that although homozygosity for a null allele in Hey2 Ϫ/Ϫ mice results exclusively in membranous VSD, all 3 defects in the double heterozygotes were ostium secundum ASDs. We performed a second cross of a double heterozygous Creld1 ϩ/Ϫ , Hey2 ϩ/Ϫ mouse to Hey2 ϩ/Ϫ . Ten pups were recovered that were homozygous for the Hey2 null allele (which is expected to produce membranous VSD) and heterozygous at Creld1 (Table  2) . Of the 10, 1 had a normal heart and 9 had membranous VSDs; for those 9 mice with membranous VSDs, 1 also had an ostium secundum ASD, and 1 had a muscular VSD in addition to membranous involvement. This result suggests that reducing Creld1 expression affected the pattern of defects in homozygous Hey2 null mice, providing further support for an interaction between Creld1 and Hey2.
Creld1 Interaction With Hey2
Creld1 encodes a cell-surface protein, and Hey2 is a nuclear transcription factor. Both are normally expressed in the heart during development and throughout life. We assessed transcript levels of both genes in hearts of mutant mice. As expected, Creld1 RNA expression was reduced in Creld1 ϩ/Ϫ mice, but, surprisingly, so was the expression of Hey2 (Figure  4) . The reverse was true, as well; Hey2 and Creld1 both showed reduced expression in hearts of Hey2 ϩ/Ϫ mice. We saw no difference in expression of Creld1 or Hey2 in Ts65Dn compared with euploid hearts from mice that did not have the Creld1 or Hey2 null alleles.
To explain the coregulation of Creld1 and Hey2, we considered the Notch signaling pathway. Binding of a ligand to the Notch receptor causes cleavage and release of a transcriptional activator domain that, with further processing, is transported to the nucleus to activate transcription of target genes, including Hey2. 21 Since Hey2 expression was downregulated in Creld1 ϩ/Ϫ mice, we assessed the transcript level of Notch1 and found it was also downregulated in these mice (Figure 4 ). This raises the possibility that Creld1 might affect Hey2 expression through the Notch pathway.
Since Creld1 was downregulated in Hey2 ϩ/Ϫ mice, we also tested whether Hey2 might be a transcription factor for Creld1. 22 Creld1 is expressed in L-cells. Transfection of a pCS2 ϩ /Hey2 construct into L-cells significantly increased the Creld1 mRNA expression by 1.9-fold compared with cells transfected with pCS2 ϩ alone ( Figure 5 ).
Discussion
Heart development is complex, and a complete genetic explanation for isolated CHD, which is generally believed to be a multifactorial condition, has proven to be a challenge; however, it is clear from extensive work with mutant mice that genetic background (modifiers) has a significant influence on both the type and the frequency of heart defects for a given mutation. For example, mice carrying mutant alleles of Tbx5, Nkx2.5, or Hey2 show different outcomes both in terms of prevalence and also in changes in the timing or location of the maldevelopment when the same mutant allele is bred onto different genetic backgrounds. 20, 23, 24 The high incidence but incomplete penetrance of CHD in the DS population suggests that variations at disomic loci (ie, on chromosomes other than Hsa21) may act as genetic modifiers in combination with trisomic genes. In other words, DS, the leading risk factor for CHD, in general, and septal defects in particular, represents a sensitizing genetic condition.
Numerous studies in mouse models have shown that genetic background can affect the severity of heart defects. 24 For example, the phenotype and survival rate of Hey2 Ϫ/Ϫ mice is strongly influenced by genetic background, with the highest mortality rates observed on C57BL/6 or 129Sv/J inbred backgrounds. 11, 12, 16, 19, 20 The correlation of variable phenotypes with different inbred backgrounds supports the idea that (disomic) allelic variants modify Hey2 function. Similarly, heterozygous Nkx2.5 knockout mice frequently have septal defects when the mutation is bred onto the B6 background, but the prevalence is substantially reduced in a first-generation (F1) outcross to FVB/N or A/J. 24 In people, CRELD1 mutations have been specifically associated with AVSD 2,8 ; however, this may be an ascertainment bias since most studies have focused on AVSD, and more partial AVSDs have been analyzed than complete AVSDs. Most CRELD1 missense mutations have been found in individuals with a partial AVSD (ostium primum ASD), occurring in ϳ2% (5/253) of cases from multiple studies. 7, [25] [26] [27] CRELD1 mutations are also found in ϳ2.5% (4/159) of complete AVSD cases studied, including Heterotaxy syndrome-associated AVSD and AVSD in Down syndrome. 7, 25, 28 There were no CRELD1 mutations identified in a study of 110 individuals with isolated ostium secundum ASD. 29 Although only membranous VSD is reported in Hey2 Ϫ/Ϫ mice, 16, 19, 20 introduction of a null allele of Hey2 into Ts65Dn mice caused muscular VSD and ASD in addition to membranous VSD. Further, the structural defect noted in Hey2 ϩ/Ϫ , Creld1 ϩ/Ϫ mice was secundum ASD. It will be instructive to determine whether timing or levels of expression, or the small structural differences in Creld1 or Hey2 proteins between mouse and human might contribute to these differences. Either way, a requirement for regulated Creld1 and Hey2 expression to achieve normal septation is clearly demonstrated here.
It should be possible to further localize the dosagesensitive (trisomic) genetic modifiers present on the T65Dn marker chromosome by introducing Creld1 or Hey2 mutations onto other trisomic models of Down syndrome with smaller segmental trisomies, such as Ts65Dn/Ms1Rhr, Ts1Cje, and Ts1Rhr. 30, 31 These mice overexpress subsets of the genes upregulated in Ts65Dn mice. The absence of AVSD in Ts65Dn mice may reflect the fact that they are trisomic for orthologs of only about half of Hsa21 genes. Mouse models trisomic for Hsa21-orthologous segments of Mmu17 and Mmu10 and for all of the Hsa21 orthologs on Mmu16 will prove useful to further characterize the contributions of dosage-sensitive genes to CHD. 13, 32, 33 These then become candidates for resequencing in the DS case and control populations described here.
The Ts65Dn populations generated in these studies will also be useful in the genome-wide search for disomic modifiers. As in our DS case and control human populations, we have generated trisomic Ts65Dn, Creld1 ϩ/Ϫ mice with and without septal defects that can be used for a genome-wide study of quantitative trait loci (QTLs) that explain the presence or not of CHD on this background. The 2 disomic modifiers, Creld1 and Hey2, showed coregulation at the transcript level. These alterations might involve the Notch signaling pathway since Notch1 is a major transcription factor for Hey2. In that regard, it is interesting that the structure of Creld1, a predicted transmembrane protein with 4 EGF-like repeats in its extracellular domain, 6 is reminiscent of the noncanonical Notch ligands, DNER 34 and DLK-1. 35 Like CRELD1, both of these lack the DSL motif of canonical Notch ligands but contain tandem EGF repeats. We tried to determine whether CRELD1 is a noncanonical ligand of Notch1; however, we could not demonstrate a physical interaction of CRELD1 and Notch1 via co-IP nor a functional one using a Notch transcription reporter assay 36 (data not shown).
Our results support a threshold hypothesis in which multiple genetic variants that are themselves benign can interact in an additive manner to produce a structural defect in the heart (Figure 1 ). We identify 2 such candidates, Creld1 and Hey2. The deleterious effects of mutations in Creld1 that were themselves insufficient to produce CHD were uncovered in human beings while Hey2 effects were first demonstrated in mice. Biological proof for interactions of both genes with trisomy and for direct interactions on a euploid background was obtained using mouse models. In combination, the benign single variants exhibit additive effects resulting in CHD in euploid individuals. This is 1 of several examples of how the genetic legacy of people with DS contributes to the health of the general population.
